AbCellera Biologics Inc. Capital Expenditures
AbCellera Biologics Inc. (ABCL) reported Capital Expenditures of $5.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $2.13M, a 84.05% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $3.83M, a 63.98% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $9.84M, a 37.02% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $8.93M, a 51.78% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $42.77M, a 45.44% decline from fiscal 2024.
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $78.40M, a 1.88% increase from fiscal 2023.
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $76.95M, a 8.90% increase from fiscal 2022.
- AbCellera Biologics Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $70.66M, a 20.89% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.96M 10-Q · filed 2026-08-05 | $15.81M derived: sum of 3 quarters · filed 2026-08-05 | $24.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.83M 10-Q · filed 2026-05-11 | $13.67M derived: sum of 2 quarters · filed 2026-05-11 | $22.60M derived: sum of 3 quarters · filed 2026-05-11 | $35.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $9.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $18.77M derived: sum of 2 quarters · filed 2026-02-24 | $32.14M derived: sum of 3 quarters · filed 2026-08-05 | $42.77M 10-K · filed 2026-02-24 |
| 2025-09-30 | $8.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.29M derived: sum of 2 quarters · filed 2026-08-05 | $32.93M 10-Q · filed 2025-11-06 | $48.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $13.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $24.00M 10-Q · filed 2026-08-05 | $39.63M derived: sum of 3 quarters · filed 2026-08-05 | $58.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.64M 10-Q · filed 2026-05-11 | $26.27M derived: sum of 2 quarters · filed 2026-05-11 | $44.78M derived: sum of 3 quarters · filed 2026-05-11 | $64.89M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $15.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $34.15M derived: sum of 2 quarters · filed 2026-02-24 | $54.26M derived: sum of 3 quarters · filed 2026-02-24 | $78.40M 10-K · filed 2026-02-24 |
| 2024-09-30 | $18.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $38.63M derived: sum of 2 quarters · filed 2025-11-06 | $62.77M 10-Q · filed 2025-11-06 | $77.20M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $20.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $44.25M 10-Q · filed 2025-08-07 | $58.68M derived: sum of 3 quarters · filed 2026-02-24 | $79.01M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $24.14M 10-Q · filed 2025-05-08 | $38.57M derived: sum of 2 quarters · filed 2026-02-24 | $58.90M derived: sum of 3 quarters · filed 2026-02-24 | $86.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $14.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $34.76M derived: sum of 2 quarters · filed 2026-02-24 | $61.96M derived: sum of 3 quarters · filed 2026-02-24 | $76.95M 10-K · filed 2026-02-24 |
| 2023-09-30 | $20.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $47.53M derived: sum of 2 quarters · filed 2024-11-04 | $62.52M 10-Q · filed 2024-11-04 | $74.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $27.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $42.19M 10-Q · filed 2024-08-06 | $54.52M derived: sum of 3 quarters · filed 2025-02-27 | $67.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $14.98M 10-Q · filed 2024-05-07 | $27.31M derived: sum of 2 quarters · filed 2025-02-27 | $39.83M derived: sum of 3 quarters · filed 2025-02-27 | $71.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $12.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $24.84M derived: sum of 2 quarters · filed 2025-02-27 | $56.16M derived: sum of 3 quarters · filed 2025-02-27 | $70.66M 10-K · filed 2025-02-27 |
| 2022-09-30 | $12.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $43.84M derived: sum of 2 quarters · filed 2023-11-02 | $58.33M 10-Q · filed 2023-11-02 | $67.76M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $31.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $45.82M 10-Q · filed 2023-08-03 | $55.25M derived: sum of 3 quarters · filed 2024-02-20 | $63.82M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $14.49M 10-Q · filed 2023-05-04 | $23.93M derived: sum of 2 quarters · filed 2024-02-20 | $32.50M derived: sum of 3 quarters · filed 2024-02-20 | $69.30M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $9.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $18.00M derived: sum of 2 quarters · filed 2024-02-20 | $54.81M derived: sum of 3 quarters · filed 2024-02-20 | $58.45M 10-K · filed 2024-02-20 |
| 2021-09-30 | $8.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $45.38M derived: sum of 2 quarters · filed 2022-11-08 | $49.02M 10-Q · filed 2022-11-08 | $50.52M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $36.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $40.45M 10-Q · filed 2022-08-09 | $41.95M derived: sum of 3 quarters · filed 2023-02-21 | $45.84M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $3.64M 10-Q · filed 2022-05-10 | $5.15M derived: sum of 2 quarters · filed 2023-02-21 | $9.03M derived: sum of 3 quarters · filed 2023-02-21 | $12.73M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $5.39M derived: sum of 2 quarters · filed 2023-02-21 | $9.09M derived: sum of 3 quarters · filed 2023-02-21 | $9.67M 10-K · filed 2023-02-21 |
| 2020-09-30 | $3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $7.59M derived: sum of 2 quarters · filed 2021-11-10 | $8.17M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $4.29M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $583.00K 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $4.00M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |